Literature DB >> 8678711

Recurrent pneumococcal bacteremia. A warning of immunodeficiency.

M Rodríguez-Créixems1, P Muñoz, E Miranda, T Peláez, R Alonso, E Bouza.   

Abstract

BACKGROUND: Recurrent pneumococcal infections are known to occur occasionally in patients with profound immune defects. We performed a case-control analysis of recurrent pneumococcal bacteremias). PATIENTS AND METHODS: The 547 episodes of Streptococcus pneumoniae bacteremia detected from January 1, 1985, to December 31, 1994, were reviewed. We selected all cases with more than 1 episode separated by 30 days or more ("cases") and compared each of them with 2 controls (patients with single episodes of pneumococcal bacteremia).
RESULTS: Fifteen patients (2.8%) had 31 episodes of pneumococcal bacteremia. Except for multiple myeloma (P < .02), the underlying disease was remarkably similar among patients with single and recurrent episodes of pneumococcal bacteremia. However, among patients positive for human immunodeficiency virus infection, those who had recurrences were at a more advanced stage of their disease than those who did not. The presence of an ultimately fatal underlying condition was more frequent in case patients (P < .001). Overall, 47% of the patients with recurrences died during their second episode of pneumococcal bacteremia.
CONCLUSIONS: Our data suggest that recurrence is more than anecdotal in patients with bacteremic infections caused by S pneumoniae (2.8%). We believe that recurrence is a warning sign of immunodeficiency. Patients with multiple myeloma, human immunodeficiency virus infection, solid organ tumors, and chronic liver disease with bacteremic pneumococcal infections should be offered antipneumococcal vaccine and other potentially preventive measures, despite doubts about their efficacy. This is justified by the high mortality rate associated with recurrent episodes (47%).

Entities:  

Mesh:

Year:  1996        PMID: 8678711     DOI: 10.1001/archinte.1996.00440120087008

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

1.  IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease.

Authors:  Cheng-Lung Ku; Capucine Picard; Melinda Erdös; Axel Jeurissen; Jacinta Bustamante; Anne Puel; Horst von Bernuth; Orchidée Filipe-Santos; Huey-Hsuan Chang; Tatiana Lawrence; Marc Raes; László Maródi; Xavier Bossuyt; Jean-Laurent Casanova
Journal:  J Med Genet       Date:  2006-09-01       Impact factor: 6.318

Review 2.  The Roles of T cells in Bladder Pathologies.

Authors:  Jianxuan Wu; Soman N Abraham
Journal:  Trends Immunol       Date:  2021-02-01       Impact factor: 16.687

3.  Recurrent pneumococcal invasive disease in the region of Madrid during a five-year period.

Authors:  J C Sanz; I Rodríguez-Avial; E Ríos; B Ramos; E Cercenado
Journal:  Infection       Date:  2013-12-22       Impact factor: 3.553

4.  Local induction of bladder Th1 responses to combat urinary tract infections.

Authors:  Jianxuan Wu; Chunjing Bao; R Lee Reinhardt; Soman N Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-09       Impact factor: 11.205

5.  Recurrent invasive pneumococcal disease in children: underlying clinical conditions, and immunological and microbiological characteristics.

Authors:  Laia Alsina; Maria G Basteiro; Hector D de Paz; Melania Iñigo; Mariona F de Sevilla; Miriam Triviño; Manel Juan; Carmen Muñoz-Almagro
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

6.  Missed Opportunities? A Retrospective Study Into Adults Hospitalized With Invasive Infection From Airway Pathogens.

Authors:  Emma L Smith; Bryan Tan; Alysia Bastas; Despina Kotsanas; Claire Dendle; Samar Ojaimi
Journal:  Open Forum Infect Dis       Date:  2022-07-05       Impact factor: 4.423

7.  Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto.

Authors:  Agron Plevneshi; Tomislav Svoboda; Irene Armstrong; Gregory J Tyrrell; Anna Miranda; Karen Green; Donald Low; Allison McGeer
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.